Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

Latest from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins


Emerging TROP-2 Directed ADCs Show Promise in Advanced NSCLC

November 28, 2023

Benjamin Philip Levy, MD, discusses the current landscape of emerging antibody-drug conjugates (ADCs) and their early activity in advanced lung cancer, the potential utility of oncogene-directed ADCs for patients with driver mutations, and more.

Dr Levy on the Ongoing Development of TROP-2 ADCs in NSCLC

November 14, 2023

Benjamin Philip Levy, MD, discusses the ongoing development of the TROP-2 directed antibody-drug conjugates sacituzumab govitecan-hziy and datopotamab deruxtecan in non–small cell lung cancer, their different toxicity profiles, as well as the potential categorization of emerging ADCs as onco-directed therapies in this patient population.

x